Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
$20.38
-$0.31(-5.78%)
At close: 4:00 PM EST
$20.38
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$2.88 - $24.00
Previous CloseN/A
Volume146.35K
Average Volume (3M)650.79K
Market Cap
$850.92M
Enterprise Value$522.29M
Total Cash (Recent Filing)$285.78M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding41,752,472
10 Day Avg. Volume499,625
30 Day Avg. Volume650,794
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue88.27
Enterprise Value/Gross Profit88.27
Enterprise Value/Ebitda-6.99
Forecast
1Y Price Target
$46.60Price Target Upside128.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$71.04M
Bulls Say, Bears Say
Bulls Say
CNS And Ophthalmology PotentialDemonstrated brain penetration and preclinical preservation of retinal microvasculature support the possibility of an oral therapy that could reduce reliance on intravitreal injections for retinal diseases.
Commercial Expansion And Combination StrategyA development plan targeting multiple indications and testing combination regimens with established therapies creates several commercial pathways that could broaden market opportunity.
Phase 1 Clinical DataPhase 1 healthy volunteer results showed clean safety and strong suppression of inflammatory biomarkers, supporting once‑daily dosing and potential to lower cardiovascular risk.
Bears Say
Analyst And Reporting ConflictsBusiness relationships between the reporting firm and covered companies create potential conflicts of interest that may affect the perceived objectivity of analyst recommendations.
Clinical And Regulatory UncertaintyReliance on multiple clinical readouts and regulatory decisions increases the chance that unfavorable trial results or approval hurdles could significantly delay development and damage investor sentiment.
Ophthalmology Proof‑of‑concept RiskA proof‑of‑concept study is required to show retinal benefit from oral dosing in diabetic macular edema, and failure to demonstrate meaningful retinal impact would undermine the ophthalmology expansion thesis.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $24.00 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $850.92M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 13 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.584 by $0.024.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.74.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 41,752,472 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.584. Following the earnings report the stock price went down -2.811%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.60 (128.66% Upside)
$46.60 (128.66% Upside)
Blogger Sentiment
Bearish
BIOA Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 24.6%
Last 30 Days ▲ 24.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
371.36%
12-Months-Change
Fundamentals
Return on Equity
-25.64%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$46.60
▲(128.66% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
10.16% Insiders
5.86% Mutual Funds
10.17% Other Institutional Investors
66.99% Public Companies and
Individual Investors